## JAZZ: Jazz Pharmaceuticals plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.1% below STRENGTH zone (4.0-10.0%); PEG 3.94 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (56% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($159.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Jazz Pharmaceuticals (JAZZ): Valuation Check After Positive Ziihera and Epidiolex Clinical Updates Boost Investor Interest**
- Source: Simply Wall Street | 20251214T230918 | Bullish | Relevance: 100%
- Jazz Pharmaceuticals (JAZZ) has experienced increased investor interest and a significant stock price rally following positive clinical updates for Epidiolex and Ziihera. Despite this rally, the stock still trades nearly 30% below consensus targets, suggesting a potential undervaluation with a fair value estimated at $208.50. Investors are now evaluating whether this presents a timely entry point or if future growth is already factored into its current price.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Piper Sandler | $219 | $147 | +49% |
| 2025-11-24 | UBS | $188 | $163 | +15% |
| 2025-11-18 | Wells Fargo | $235 | $170 | +38% |
| 2025-11-18 | Baird | $209 | $160 | +31% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-11-24 | UBS | down | Neutral |
| 2025-11-18 | Wells Fargo | main | Overweight |
| 2025-11-18 | Baird | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 13 ($5.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.7% (-3.0%)
- Blackrock Inc.: 9.2% (-4.2%)
- JPMORGAN CHASE & CO: 6.2% (+117.0%)
- Dimensional Fund Adv: 4.7% (+11.8%)
- Capital World Invest: 4.2% (+0.4%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Valuation stretched: PEG 3.9x requires aggressive growth execution.
3. Elevated short interest (9.5%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 6 raises (avg +25%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.94 signals overvaluation risk, limited margin of safety. Forward P/E 7.5x attractive for 180% earnings growth. Analyst sentiment positive (6 raises, avg +25%). Insider selling cluster ($5.3M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.3B |
| Beta | 0.31 |
| 52W Range | $95.49 - $182.99 |
| Short Interest | 9.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.94 |
| Forward P/E | 7.5 |
| Current P/E | 21.0 |
| YoY Growth | 180.1% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -4.0% to -1.1% (+2.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.1pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.3%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.34x) but short-term weakness (below SMA20). MACD histogram bearish (-1.49), momentum weakening. RSI neutral at 60. Volume at 56% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.11% (CS: 33) | Neutral |
| RSI_14 | 60.0 | Neutral |
| MACD Histogram | -1.49 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 1.121x | Above |
| vs SMA200 | 1.344x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $169.73
- **Stop Loss:** $159.45 (6.1% risk)
- **Target:** $180.01 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 97
- **Position Value:** $16,463.81
- **Portfolio %:** 16.46%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-24 (Est: $6.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.85 | $8.13 | +39.0% |
| 2025Q2 | $-6.25 | $-8.25 | -32.1% |
| 2025Q1 | $4.66 | $1.68 | -63.9% |
| 2024Q4 | $5.81 | $6.60 | +13.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*